RxDoctor Payments DataLook up a doctor →

Michael Fox, DO

Addiction Medicine · Livonia, MINPI 1558444711

Payments from drug & device makers

$38,775in general payments, 2019–2025

Across 645 payments — averaging $60.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$14K
  • Alkermes, Inc.$10K
  • Orexo US, Inc.$4K
  • AbbVie$2K
  • Stryker$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$5,83015%
  • Speaking & faculty fees$16,77543%
  • Travel & lodging$4,18911%
  • Food & beverage$11,47530%
  • Gifts$5061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,775 in reported general payments places this provider in the 95th percentile of 62 addiction medicine providers in Michigan.

See all addiction medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$137,933
Medicare patients
174
Services billed
1,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$153,134
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl820$114,316
FarxigaDapagliflozin Propanediol30$25,402
OzempicSemaglutide27$25,220
LinzessLinaclotide27$17,828
JanuviaSitagliptin Phosphate18$17,156
SuboxoneBuprenorphine Hcl/Naloxone Hcl26$16,337
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,859
XareltoRivaroxaban15$11,628
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,692
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,330
ZubsolvBuprenorphine Hcl/Naloxone Hcl24$9,304
JardianceEmpagliflozin12$7,009
Gabapentin358$2,823
Divalproex Sodium ErDivalproex Sodium54$1,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,075$153,13423 claims
AstraZenecaFarxiga, Breztri Aerosphere$799$34,73246 claims
GSKTrelegy Ellipta, Anoro Ellipta$274$25,55139 claims
Novo NordiskOzempic$301$25,22027 claims
AbbVieLinzess$2,386$17,82827 claims
MerckJanuvia$27$17,15618 claims
Indivior Inc.Suboxone$13$16,33726 claims
Johnson & JohnsonXarelto$30$11,62815 claims
Orexo US, Inc.Zubsolv$3,708$9,30424 claims
Boehringer IngelheimJardiance$56$7,00912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 addiction medicine providers in Michigan.

Other addiction medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →